RxDoctor Payments Data

Robert Coleman, DPM

Podiatrist · Greenville, SCNPI 1225075476

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Kowa Pharmaceuticals America, Inc. at 27.5% of the total. Reporting peaked in 2023 at $392 and has fallen 52.8% since, to $185 in 2025. That places this record below the midpoint for podiatrist clinicians in SC, where the typical reported total is $1,261.

$998in general payments, 2019–2025

Across 63 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$274
  • Paratek Pharmaceuticals, Inc.$190
  • Sebela Pharmaceuticals Inc.$82
  • Stryker$81
  • Treace Medical Concepts, Inc.$77
  • Melinta Therapeutics, LLC$42
  • plus $253 from 12 others

What the payments were for

  • Food & beverage$998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$998 in reported general payments places this provider in the 45th percentile of 61 podiatrist providers in South Carolina.

See all podiatrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$170,564
Medicare patients
627
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin29$157

Paid to pharmacies, not to this prescriber.

Other podiatrist in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →